American Academy of Dermatology (AAD) Innovation Academy 2026

Takeda Reports Positive Phase 3 Results for Zasocitinib in Plaque Psoriasis

Takeda Pharmaceutical has announced positive results from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 clinical trials, establishing its selective TYK2 inhibitor, zasocitinib, as a high-efficacy oral candidate for moderate-to-severe plaque psoriasis.

With approximately 70 percent of participants achieving a static Physician Global Assessment (sPGA) score of clear or almost clear by the 16-week mark, the company is preparing to initiate global regulatory filings, including a New Drug Application with the FDA, within the current fiscal year.

Also read: Germany Enacts 2026 Healthcare Reform to Curb Statutory Insurance Spending

Key Regulatory Proposals

The clinical data highlights the efficacy of zasocitinib in addressing notoriously difficult-to-treat manifestations of the disease. In addition to general skin clearance, the drug demonstrated significant superiority over both placebo and the current standard-of-care oral therapy, apremilast. Specifically, 77 percent and 74 percent of patients with scalp psoriasis achieved clinical success in the respective trials.

Similarly, approximately 70 percent of patients with palmoplantar disease achieved clearance, while those with nail psoriasis showed statistically significant improvements in the Nail Psoriasis Severity Index (NAPSI).

The drug demonstrated rapid clinical activity, with PASI 75 responses occurring as early as week 4 and continuing to improve through week 24, suggesting a profile of durable long-term efficacy. From a safety perspective, the trial reported no new signals, with common adverse events limited to nasopharyngitis, upper respiratory infections, and acne.

Also read: Top 10 pharmaceutical companies by revenues in 2026

Market & Clinical Implications

The introduction of an oral treatment that mirrors the efficacy of injectable biologics is expected to trigger a significant shift in site-of-care dynamics.

Industry Context

Takeda’s strategic development of zasocitinib signals a broader industry transition toward potent, selective small-molecule therapies capable of closing the performance gap with conventional biologics.

By demonstrating superior efficacy against existing oral therapies like apremilast, zasocitinib is expected to exert significant pressure on the current treatment algorithm upon its eventual market entry.

Beyond psoriasis, Takeda is positioning zasocitinib as a core pillar of its immunology franchise, with ongoing investigations into its efficacy for Crohn’s disease, ulcerative colitis, psoriatic arthritis, vitiligo, and hidradenitis suppurativa.